Vertex Pharmaceuticals Inc (VRTX)
Vertex Pharmaceuticals Inc (VRTX) carries a ŷRobot AI score of 71 out of 100. The model's fair value estimate is $545.57, 9.4% above the last close of $498.50. The chart signal reads Hold.
| Metric | VRTX |
|---|---|
| AI score | 71 / 100 |
| Chart signal | Hold |
| Fair value estimate | $545.57 |
| Upside to fair value | 9.4% |
| Previous close | $498.50 |
| P/E | 29.74 |
| Price / sales | 10.20 |
| Market cap | $128.50B |
| EPS | 17.04 |
| Revenue growth | 10.1% |
| 1-year price change | 8.4% |
How these numbers are built: the AI score, the fair value model, and the chart signal.
Other Healthcare stocks: Eli Lilly and Company, Johnson & Johnson, AbbVie Inc, UnitedHealth Group Incorporated, Merck & Company Inc, Novartis AG ADR.
Questions about VRTX
Is VRTX overvalued or undervalued right now?
As of Oct 14, 2026, ŷRobot's fair-value model estimates Vertex Pharmaceuticals Inc (VRTX) at $545.57 against a last close of $498.50, implying 9.4% upside to the model's estimate.
Is VRTX's chart signal bullish or bearish?
The chart-signal model classifies VRTX as Neutral as of Oct 14, 2026, with a signal score of 0.01 on a -1 to 1 scale.
What is VRTX's ŷRobot AI score?
VRTX scores 71 out of 100 on ŷRobot's AI composite, which measures how strongly the fair-value and chart models agree, as of Oct 14, 2026.
Is VRTX stock expensive on P/E and P/S?
VRTX trades at 29.7 times earnings and 10.2 times sales as of Oct 14, 2026.
What does VRTX's seasonal forecast show?
ŷRobot's seasonal forecast curve for VRTX reads -0.9% at 30 days, +2.6% at 90 days, and +8.4% at one year as of Oct 14, 2026. Seasonal tendencies are historical patterns, not predictions.
How fast is VRTX growing?
Vertex Pharmaceuticals Inc's revenue growth is +10.1% and free-cash-flow growth is -5.1% on the latest reported figures.
VRTX chart and technical read · All covered stocks
ŷRobot analysis is AI-generated and quality-gated; nothing here is investment advice.